培土清心方对特应性皮炎患者血清n-6 EFAs及行为的影响
|
摘要
研究背景
特应性皮炎(atopic dermatitis, AD)是一种慢性、复发性、瘙痒性皮肤病,严重影响着患者的身体、心理、行为等多方面的健康。近年来AD发病率呈逐年上升趋势,因其发病机制尚不明确,西医治疗只能在一定程度缓解症状,对于顽固病例则不能取得满意疗效。中医药作为一种有效治疗方法,不仅能够缓解症状,而且能够改善患者生活质量,被越来越多的用于治疗特应性皮炎的临床和实验研究,因此关于本病的中医治疗已成为研究的热点。目前国外对中医中药的研究比较深入,研究人员发现单味中药或者有限的几味中药提取物组成的复方确有疗效,尤其在抗炎及免疫调节方面的作用得到了肯定。国内中医药治疗AD多为辨证论治、经验方研究,其具体作用机理尚待阐明。培土清心法是导师陈达灿教授多年临床实践中的经验总结,具有较好的临床疗效。近年来关于AD的发病机理在免疫方面研究有了较大进展,与此同时也发现营养代谢因素在AD的发病过程中也有着重要的作用,中医药治疗疾病是多靶点的,本研究通过检测AD患者治疗前后的n-6脂肪酸水平的变化,探讨培土清心方治疗特应性皮炎可能的作用机理；AD作为一种心身疾病,剧烈的瘙痒、睡眠紊乱以及病情的反复给患者心身造成了巨大的压力,行为学的异常是疾病困扰患者的一种外在表现,也是影响患者生活质量很重要的一方面,目前逐步引起人们的重视,本研究也通过治疗前后患者行为学的变化以探讨中药培土清心方对AD行为的影响。
临床研究
目的
了解特应性皮炎儿童患者行为情况,观察培土清心方治疗特应性皮炎的临床疗效及治疗后患者行为的变化。
方法
临床疗效观察：本研究选择6—11岁AD患者为研究对象,用中药培土清心方内服,辅以润肤剂外用治疗,以SCORAD积分进行评价,治疗前及治疗后3个月分别记录SCORAD积分及主观症状的变化。
对行为学的影响：所有患者治疗前及治疗后由父母填写Conners父母用症状问卷,并与中国城市常模进行比较,并将治疗前Conners父母用症状问卷得分与SCORAD积分及主观症状积分(瘙痒与睡眠积分之和)进行相关分析。
结果
1、本临床观察共纳入36例符合标准的AD患者,采用中药培土清心方内服治疗,结果显示治疗后患者SCORAD积分及主观症状较治疗前均明显下降,差异均有统计学意义(P＜0.01)。
2、治疗前AD患者Conners父母用症状问卷积分项目中,男女儿童患者冲动—多动、多动指数均高于中国常模,差异均有统计学意义(P＜0.05),AD儿童品行问题、学习问题、心身问题、焦虑与常模比较差异均无统计学意义(P＞0.05)
3、相关分析：男女AD儿童的多动指数与患者主观症状存在中度正相关(男：r=0.610,P＜0.05；女：r=0.533,P＜0.05)；多动指数与SCORAD积分无相关性。
4、治疗后,男女儿童患者冲动—多动、多动指数均较前下降,差异均有统计学意义(P＜0.01)；说明培土清心方对于AD多动行为有改善作用,治疗后男女儿童患者冲动—多动、多动指数仍高于中国常模,差异有统计学意义(P＜0.05)。
结论
1、中药培土清心方内服治疗AD,患者治疗后较治疗前SCORAD积分及主观症状明显下降,差异有统计学意义,验证了培土清心法治疗AD疗效的可靠性。
2、AD患者存在多动行为,其中多动指数与主观症状严重程度有关。
3、培土清心方在一定程度上能改善AD患者的多动行为。
实验研究
目的
总IgE升高的AD患者存在着n—6脂肪酸代谢的异常,通过检测AD患者治疗前后的n—6脂肪酸水平的变化,探讨培土清心方治疗特应性皮炎可能的作用机理。
方法
选取血清总IgE升高的AD患者于治疗前及治疗3个月时,以20例健康志愿者为对照,采用ELISA法检测血清中亚油酸(LA)、Y-亚油酸(GLA)、二高亚油酸(DGLA)、花生四烯酸(AA)水平,并将各项血清学指标与患者SCORAD积分进行相关分析。
结果
1、本临床观察共纳入22例符合标准的AD患者,治疗前AD患者血清中LA水平与正常对照组比较差异无统计学意义(P＞0.05),说明AD患者从饮食中摄入的LA正常,血清中GLA水平均低于正常对照组,差异有统计学意义(P＜0.05),血清中DGLA、AA水平与正常组比较差异无统计学意义(P＞0.05),进一步统计得出GLA/LA水平低于正常对照组,差异有统计学意义(P＜0.05),说明A-6去饱和酶存在缺陷;AA/DGLA水平与正常组比较,差异无统计学意义(P＞0.05),说明△-5去饱和酶功能正常。
2、相关性分析：血清GLA与SCORAD积分存在中度负相关(r=—0.528,P<0.05)。血清LA、DGLA、AA水平与SCORAD积分无相关性。
3、治疗后患者血清中GLA较治疗前升高,GLA/LA水平较治疗前升高,差异有统计学意义(P＜0.05),说明培土清心方可能对△-6去饱和酶起到了一定的调节作用,从而升高血清GLA水平。
结论
1、再次证实IgE升高的AD患者n—6必需脂肪酸代谢存在异常,GLA水平的减少是AD发病的机理之一。
2、AD患者血清GLA水平与SCORAD积分的相关关系分析结果显示存在中度负相关,提示GLA与AD病情严重程度有关。
3、通过培土清心方治疗后,患者血清GLA水平较前升高,GLA/LA水平较治疗前升高,说明培土清心方可能对△-6去饱和酶起到了一定的调节作用,可以升高血清GLA水平,从而起到抗炎及免疫调节作用而缓解病情,推测这可能为培土清心法治疗AD的作用机理之一。
Background
Atopic dermatitis (AD) is a chronically relapsing and pruritic inflammatory skin disease. Which has a serious effect on patients'physical、psychological and behavior health. The incidence of the disease is steadily increasing in recent years. While no confirmative mechanism of the disease was generally accepted.the western medicine for atopic dermatitis is just to ameliorate symptoms during the flare of the disease, but for the Serious illness, the Efficacy is not well. As an effective treatment, Chinese medicine can not only relieve symptoms but also improve quality of life. So, Chinese medicine has been used to the treatment of atopic dermatitis in clinical and experimental research, therefore Chinese herb for treatment of atopic dermatitis becomes the warm spot due to its unique superiority. Chinese medicine is currently abroad on more in-depth study, the researchers found that a single Chinese medicine or a limited number of extract composition of traditional Chinese medicine are effective, especially the anti-inflammatory and immune regulating role were confirmed. However, in our country, most researches in this field revolve around clinical observation of therapeutic effects by experiential prescription, the specific mechanism remains to be clarified, formula of hilling and clearing away heart-fire for atopic dermatitis has been proved to be effective.which is experience of Professor Chen Da—can for many years in clinical practice. In recent years about the pathogenesis of AD in the immunization studies have made great progress,at the same time, Researchers found that nutrient metabolic factors in the pathogenesis of AD also has an important role, Serum n-6 essential fatty acids levels before and after treatment of the formula were tested to further explore mechanism related to the treatment. As a psychosomatic disease, severe itching, sleep disorders, as well as the Relapse repeatedly have caused tremendous psychological pressure to AD patients, the abnormal behavior is an outward manifestation of Psychosomatic disorders, which also affects the quality of life of patients. therefore, Abnormal behavior gradually attracted people's attention. we investigate the changes of AD patient in Behavior problems before and after treatment and discuss the effect of the formula of hilling and clearing away heart-fire for atopic dermatitis on behavioral symptoms.
Clinical Research
Objective
The purpose of the research was to investigate the behavior problems Of the AD patient, to observe the effects of the formula of hilling and clearing away heart-fire Treatment of atopic dermatitis and its effect on behavioral symptoms.
Methods
Clinical Observation:patients of 6-11 years old who were diagnosed with atopic dermatitis were selected to this clinical trial. Scores of AD index were collected before treatment and after treatment for three months respectively.
The impact on behavior:Behavioral problems were evaluated by the Conners Parent Symptom Questionnaire before and after treatment. Then, compared the index with the Chinese urban norm.
The correlation test were calculated to evaluate the correlation between the hyperactivity index and the SCORAD index, between the hyperactivity index and the subjective symptoms index.
Results
1、36 patients suffered from atopic dermatitis were included to the clinical trial and treated with formula of the Hilling and clearing away heart-fire and adjuvant emollient. SCORAD index was used to evaluated clinical therapeutic outcomes. After treatment, The SCORAD index and Subjective symptoms declined significant (P＜0.01). So it is demonstrates that the method of hilling and clearing away heart-fire had confirmative effects on the atopic dermatitis.
2、before treatment, the impulsivity—hyperactivity index and hyperactivity index of the boys and girls were higher than the norm in China, the differences were statistically significant (P＜0.05).
3、Correlation Analysis:there was a moderate positive correlation between hyperactivity index and subjective symptoms index. (boys:r=0.610, P＜0.05; girls:r=0.533, P＜0.05). there was no correlation between hyperactivity index and the SCORAD index.
4、After treatment, the impulsivity—hyperactivity index and hyperactivity index of the boys and girls decreased compared with before respectively. The difference was statistically significant respectively (P＜0.05).Which shows the formula of hilling and clearing away heart-fire for the AD can improve hyperactive behavior. The impulsivity—hyperactivity index and the hyperactivity index was still higher than the Chinese norm respectively,The difference was statistically significant (P＜0.05).
Conclusions
1、The formula of hilling and clearing away heart-fire has confirmative therapeutic effect on AD patients.
2、AD patients show hyperactivity behavior. The level of hyperactivity index in AD patients was moderate positive associated with subjective symptom index.
3、The formula of hilling and clearing away heart-fire can improve hyperactive behavior of AD patients.
Experimental study
Objective
AD patients with elevated total IgE exist n-6 essential fatty acid metabolism abnormalities. Detect the level of n-6 fatty acid of patients with atopic dermatitis before and after treatment to discuss potential therapeutic mechanisms of formula of hilling and clearing away heart-fire.
Methods
1、patients who were diagnosed with atopic dermatitis with elevated total serum IgE were selected to this clinical trial. The serum of samples were collected from atopic dermatitis and 20 healthy people. The serum of linoleic acid (LA),γ-linoleic acid (GLA),two high-linoleic acid (DGLA), arachidonic acid(AA) in the patients and health controls were detected by ELISA.
2、The Spearman rank correlation test were calculated to evaluate the correlation between n-6 EFA composition and the SCORAD index.
Results
1、Before treatment, there was no significant difference of LA level between AD patients and control group (P>0.05); serum level of GLA in AD group was lower than the control group, the difference was statistically significant(P <0.01), there was no significant difference of serum levels of DGLA、AA between AD patient and the control group respectively(P>0.05). The GLA/LA ratio was lower than the control group, the difference was statistically significant (P＜0.05), The AA/DGLA ratio not statistically significant between the AD groups and the control group(P>0.05).
2、Correlation Analysis:there was a negative correlation between serum level of GLA and the score of SCORAD (r=-0.528, P＜0.05).The SCORAD index did not showed a correlation with serum levels of LA、DGLA and AA (all P>0.05).
3、After treatment, the level of serum GLA increased than before, the difference was statistically significant (P<0.01). the GLA/LA ratio was higher than before treatment, the difference was statistically significant(P＜0.05).
Conclusions
1、It's demonstrated again in this study that AD patients with elevated total IgE exist n-6 EFAs metabolism abnormality. the lower GLA level is one of the pathogenesis of AD.
2、The level of GLA in AD patients is moderate positive associated with the score of SCORAD index. And they also has association with severity of AD.
3、The serum level of GLA obviously was elevated after treatment with the formula of hilling and clearing away heart-fire compare with before. The GLA/LA ratio increased, therefore, the formula of hilling and clearing away heart-fire can regulate△-6 desaturase, which may be possible mechanism of treat AD.
特应性皮炎(atopic dermatitis, AD)是一种慢性、复发性、瘙痒性皮肤病,严重影响着患者的身体、心理、行为等多方面的健康。近年来AD发病率呈逐年上升趋势,因其发病机制尚不明确,西医治疗只能在一定程度缓解症状,对于顽固病例则不能取得满意疗效。中医药作为一种有效治疗方法,不仅能够缓解症状,而且能够改善患者生活质量,被越来越多的用于治疗特应性皮炎的临床和实验研究,因此关于本病的中医治疗已成为研究的热点。目前国外对中医中药的研究比较深入,研究人员发现单味中药或者有限的几味中药提取物组成的复方确有疗效,尤其在抗炎及免疫调节方面的作用得到了肯定。国内中医药治疗AD多为辨证论治、经验方研究,其具体作用机理尚待阐明。培土清心法是导师陈达灿教授多年临床实践中的经验总结,具有较好的临床疗效。近年来关于AD的发病机理在免疫方面研究有了较大进展,与此同时也发现营养代谢因素在AD的发病过程中也有着重要的作用,中医药治疗疾病是多靶点的,本研究通过检测AD患者治疗前后的n-6脂肪酸水平的变化,探讨培土清心方治疗特应性皮炎可能的作用机理；AD作为一种心身疾病,剧烈的瘙痒、睡眠紊乱以及病情的反复给患者心身造成了巨大的压力,行为学的异常是疾病困扰患者的一种外在表现,也是影响患者生活质量很重要的一方面,目前逐步引起人们的重视,本研究也通过治疗前后患者行为学的变化以探讨中药培土清心方对AD行为的影响。
临床研究
目的
了解特应性皮炎儿童患者行为情况,观察培土清心方治疗特应性皮炎的临床疗效及治疗后患者行为的变化。
方法
临床疗效观察：本研究选择6—11岁AD患者为研究对象,用中药培土清心方内服,辅以润肤剂外用治疗,以SCORAD积分进行评价,治疗前及治疗后3个月分别记录SCORAD积分及主观症状的变化。
对行为学的影响：所有患者治疗前及治疗后由父母填写Conners父母用症状问卷,并与中国城市常模进行比较,并将治疗前Conners父母用症状问卷得分与SCORAD积分及主观症状积分(瘙痒与睡眠积分之和)进行相关分析。
结果
1、本临床观察共纳入36例符合标准的AD患者,采用中药培土清心方内服治疗,结果显示治疗后患者SCORAD积分及主观症状较治疗前均明显下降,差异均有统计学意义(P＜0.01)。
2、治疗前AD患者Conners父母用症状问卷积分项目中,男女儿童患者冲动—多动、多动指数均高于中国常模,差异均有统计学意义(P＜0.05),AD儿童品行问题、学习问题、心身问题、焦虑与常模比较差异均无统计学意义(P＞0.05)
3、相关分析：男女AD儿童的多动指数与患者主观症状存在中度正相关(男：r=0.610,P＜0.05；女：r=0.533,P＜0.05)；多动指数与SCORAD积分无相关性。
4、治疗后,男女儿童患者冲动—多动、多动指数均较前下降,差异均有统计学意义(P＜0.01)；说明培土清心方对于AD多动行为有改善作用,治疗后男女儿童患者冲动—多动、多动指数仍高于中国常模,差异有统计学意义(P＜0.05)。
结论
1、中药培土清心方内服治疗AD,患者治疗后较治疗前SCORAD积分及主观症状明显下降,差异有统计学意义,验证了培土清心法治疗AD疗效的可靠性。
2、AD患者存在多动行为,其中多动指数与主观症状严重程度有关。
3、培土清心方在一定程度上能改善AD患者的多动行为。
实验研究
目的
总IgE升高的AD患者存在着n—6脂肪酸代谢的异常,通过检测AD患者治疗前后的n—6脂肪酸水平的变化,探讨培土清心方治疗特应性皮炎可能的作用机理。
方法
选取血清总IgE升高的AD患者于治疗前及治疗3个月时,以20例健康志愿者为对照,采用ELISA法检测血清中亚油酸(LA)、Y-亚油酸(GLA)、二高亚油酸(DGLA)、花生四烯酸(AA)水平,并将各项血清学指标与患者SCORAD积分进行相关分析。
结果
1、本临床观察共纳入22例符合标准的AD患者,治疗前AD患者血清中LA水平与正常对照组比较差异无统计学意义(P＞0.05),说明AD患者从饮食中摄入的LA正常,血清中GLA水平均低于正常对照组,差异有统计学意义(P＜0.05),血清中DGLA、AA水平与正常组比较差异无统计学意义(P＞0.05),进一步统计得出GLA/LA水平低于正常对照组,差异有统计学意义(P＜0.05),说明A-6去饱和酶存在缺陷;AA/DGLA水平与正常组比较,差异无统计学意义(P＞0.05),说明△-5去饱和酶功能正常。
2、相关性分析：血清GLA与SCORAD积分存在中度负相关(r=—0.528,P<0.05)。血清LA、DGLA、AA水平与SCORAD积分无相关性。
3、治疗后患者血清中GLA较治疗前升高,GLA/LA水平较治疗前升高,差异有统计学意义(P＜0.05),说明培土清心方可能对△-6去饱和酶起到了一定的调节作用,从而升高血清GLA水平。
结论
1、再次证实IgE升高的AD患者n—6必需脂肪酸代谢存在异常,GLA水平的减少是AD发病的机理之一。
2、AD患者血清GLA水平与SCORAD积分的相关关系分析结果显示存在中度负相关,提示GLA与AD病情严重程度有关。
3、通过培土清心方治疗后,患者血清GLA水平较前升高,GLA/LA水平较治疗前升高,说明培土清心方可能对△-6去饱和酶起到了一定的调节作用,可以升高血清GLA水平,从而起到抗炎及免疫调节作用而缓解病情,推测这可能为培土清心法治疗AD的作用机理之一。
Background
Atopic dermatitis (AD) is a chronically relapsing and pruritic inflammatory skin disease. Which has a serious effect on patients'physical、psychological and behavior health. The incidence of the disease is steadily increasing in recent years. While no confirmative mechanism of the disease was generally accepted.the western medicine for atopic dermatitis is just to ameliorate symptoms during the flare of the disease, but for the Serious illness, the Efficacy is not well. As an effective treatment, Chinese medicine can not only relieve symptoms but also improve quality of life. So, Chinese medicine has been used to the treatment of atopic dermatitis in clinical and experimental research, therefore Chinese herb for treatment of atopic dermatitis becomes the warm spot due to its unique superiority. Chinese medicine is currently abroad on more in-depth study, the researchers found that a single Chinese medicine or a limited number of extract composition of traditional Chinese medicine are effective, especially the anti-inflammatory and immune regulating role were confirmed. However, in our country, most researches in this field revolve around clinical observation of therapeutic effects by experiential prescription, the specific mechanism remains to be clarified, formula of hilling and clearing away heart-fire for atopic dermatitis has been proved to be effective.which is experience of Professor Chen Da—can for many years in clinical practice. In recent years about the pathogenesis of AD in the immunization studies have made great progress,at the same time, Researchers found that nutrient metabolic factors in the pathogenesis of AD also has an important role, Serum n-6 essential fatty acids levels before and after treatment of the formula were tested to further explore mechanism related to the treatment. As a psychosomatic disease, severe itching, sleep disorders, as well as the Relapse repeatedly have caused tremendous psychological pressure to AD patients, the abnormal behavior is an outward manifestation of Psychosomatic disorders, which also affects the quality of life of patients. therefore, Abnormal behavior gradually attracted people's attention. we investigate the changes of AD patient in Behavior problems before and after treatment and discuss the effect of the formula of hilling and clearing away heart-fire for atopic dermatitis on behavioral symptoms.
Clinical Research
Objective
The purpose of the research was to investigate the behavior problems Of the AD patient, to observe the effects of the formula of hilling and clearing away heart-fire Treatment of atopic dermatitis and its effect on behavioral symptoms.
Methods
Clinical Observation:patients of 6-11 years old who were diagnosed with atopic dermatitis were selected to this clinical trial. Scores of AD index were collected before treatment and after treatment for three months respectively.
The impact on behavior:Behavioral problems were evaluated by the Conners Parent Symptom Questionnaire before and after treatment. Then, compared the index with the Chinese urban norm.
The correlation test were calculated to evaluate the correlation between the hyperactivity index and the SCORAD index, between the hyperactivity index and the subjective symptoms index.
Results
1、36 patients suffered from atopic dermatitis were included to the clinical trial and treated with formula of the Hilling and clearing away heart-fire and adjuvant emollient. SCORAD index was used to evaluated clinical therapeutic outcomes. After treatment, The SCORAD index and Subjective symptoms declined significant (P＜0.01). So it is demonstrates that the method of hilling and clearing away heart-fire had confirmative effects on the atopic dermatitis.
2、before treatment, the impulsivity—hyperactivity index and hyperactivity index of the boys and girls were higher than the norm in China, the differences were statistically significant (P＜0.05).
3、Correlation Analysis:there was a moderate positive correlation between hyperactivity index and subjective symptoms index. (boys:r=0.610, P＜0.05; girls:r=0.533, P＜0.05). there was no correlation between hyperactivity index and the SCORAD index.
4、After treatment, the impulsivity—hyperactivity index and hyperactivity index of the boys and girls decreased compared with before respectively. The difference was statistically significant respectively (P＜0.05).Which shows the formula of hilling and clearing away heart-fire for the AD can improve hyperactive behavior. The impulsivity—hyperactivity index and the hyperactivity index was still higher than the Chinese norm respectively,The difference was statistically significant (P＜0.05).
Conclusions
1、The formula of hilling and clearing away heart-fire has confirmative therapeutic effect on AD patients.
2、AD patients show hyperactivity behavior. The level of hyperactivity index in AD patients was moderate positive associated with subjective symptom index.
3、The formula of hilling and clearing away heart-fire can improve hyperactive behavior of AD patients.
Experimental study
Objective
AD patients with elevated total IgE exist n-6 essential fatty acid metabolism abnormalities. Detect the level of n-6 fatty acid of patients with atopic dermatitis before and after treatment to discuss potential therapeutic mechanisms of formula of hilling and clearing away heart-fire.
Methods
1、patients who were diagnosed with atopic dermatitis with elevated total serum IgE were selected to this clinical trial. The serum of samples were collected from atopic dermatitis and 20 healthy people. The serum of linoleic acid (LA),γ-linoleic acid (GLA),two high-linoleic acid (DGLA), arachidonic acid(AA) in the patients and health controls were detected by ELISA.
2、The Spearman rank correlation test were calculated to evaluate the correlation between n-6 EFA composition and the SCORAD index.
Results
1、Before treatment, there was no significant difference of LA level between AD patients and control group (P>0.05); serum level of GLA in AD group was lower than the control group, the difference was statistically significant(P <0.01), there was no significant difference of serum levels of DGLA、AA between AD patient and the control group respectively(P>0.05). The GLA/LA ratio was lower than the control group, the difference was statistically significant (P＜0.05), The AA/DGLA ratio not statistically significant between the AD groups and the control group(P>0.05).
2、Correlation Analysis:there was a negative correlation between serum level of GLA and the score of SCORAD (r=-0.528, P＜0.05).The SCORAD index did not showed a correlation with serum levels of LA、DGLA and AA (all P>0.05).
3、After treatment, the level of serum GLA increased than before, the difference was statistically significant (P<0.01). the GLA/LA ratio was higher than before treatment, the difference was statistically significant(P＜0.05).
Conclusions
1、It's demonstrated again in this study that AD patients with elevated total IgE exist n-6 EFAs metabolism abnormality. the lower GLA level is one of the pathogenesis of AD.
2、The level of GLA in AD patients is moderate positive associated with the score of SCORAD index. And they also has association with severity of AD.
3、The serum level of GLA obviously was elevated after treatment with the formula of hilling and clearing away heart-fire compare with before. The GLA/LA ratio increased, therefore, the formula of hilling and clearing away heart-fire can regulate△-6 desaturase, which may be possible mechanism of treat AD.
引文
[1]张凡,王萍.张志礼治疗异位性皮炎经验[J].中医杂志,1998,39(7)：402-404.
[2]邢华,朱仁康.治疗异位性皮炎的经验[J].中华中医药学刊,2007,25(2)：229-230.
[3]何丹,林青,王妍.特应性皮炎的中医辨证及用药规律[J].云南中医学院学报,2009,32(4)：66-70.
[4]尤立平,刘永生,杨顶权,等.44例特应性皮炎中医临床证候分析与辨证治疗[J]中国中西医结合皮肤性病学杂志,2003,2(2)：71-73.
[5]王文革.汪受传教授治疗异位性皮炎的经验[J].中华中医药杂志,2008,23(8)：703-704.
[6]吕飞,周春燕.辨证治疗异位性皮炎[J].中国民间疗法,2004,12(6)：8-9.
[7]秦万章.先天性过敏性湿疹的证治[J].中国中西医结合杂志,2008,28(8)：677-678.
[8]Kasperska-Zajac A, Brzoza Z, Koczy-Baron E, et al. Blood Rheological Properties in Patients with Atopic Dermatitis(AD)[J]. Inflammation. 2009,32(4):242-6.
[9]姚守恩,周渐云许铣治疗异位性皮炎经验[J].实用中医药杂志,2006,22(2)：116.
[10]刘汉长.中医内外合治特应性皮炎疗效观察[J].世界中西医结合杂志,2006,1(3)：166—167.
[11]欧柏生,刘卫兵,王建民.四弯风汤联合西药治疗特异性皮炎34例[J].中国民间疗法,2006,14(1)：8-9.
[12]杨瑛,孙继兰,王麦娣,等.健脾止痒颗粒治疗特应性皮炎临床观察[J].中国皮肤性病学杂志,2005,19(12)：755-756.
[13]麻林玖,梁红梅.加味启脾丸颗粒治疗儿童特应性皮炎疗效观察[J].中国皮肤性病学杂志,2006,20(11)：698.
[14]陈文展.黛连油膏治疗异位性皮炎26例[J].福建医药杂志,2003,25(3)：224—225.
[15]关小红,张立曼.润肤止痒洗剂治疗特应性皮炎54例临床观察[J].中国中西医结合皮性病学杂志,2006,5(2)：113.
[16]陈骏铎.陆怀橘干湿法治疗异位性皮炎[J].中国民间疗法,1999,15(3)：5
[17]曾昭明,潘伟军.中药内服外用治疗异位性皮炎47例[J].新中医,2007,39(3)：56—57.
[18]Hon KL, Leung TF, Ng PC et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis:a randomized, double-blind, placebo-controlled study[J]. Br J Dermatol,2007,157(2):357-63.
[19]Leung TF, Wong KY, Wong CK, et al. In vitro and clinical immunomodulatory effects of a novel Pentaherbs concoction for atopic dermatitis[J]. Br J Dermatol,2008,158(6):1216-23.
[20]Salameh F, Perla D, Solomon M-et al. The Effectiveness of Combined Chinese Herbal Medicine and Acupuncture in the Treatment of Atopic Dermatitis[J]. J Altern Complement Med,2008,14(8):1043-8.
[21]Kim J, Kim Y, Seo D et al. Oral supplementation of Lithospermum erythrorhizon prevents the development of atopic dermatitis with reducing ceramide degradation in the epidermis of NC/Nga mice[J]. Phytother Res, 2009,23 (9):1250-6.
[22]Lee JH, Jung KM, Bae IH et al. Anti-inflammatory and barrier protecting effect of Lithospermum erythrorhizon extracts in chronic oxazolone-induced murine atopic dermatitis[J]. J Dermatol Sci,2009,56(1):64-66
[23]Kim DY, Jung JA, Kim TH et al, Oral administration of Uncariae rhynchophylla inhibits the development of DNFB-induced atopic dermatitis-like skin lesions via IFN-gamma down-regulation in NC/Nga mice[J].J Ethnopharmacol, 2009,122(3):567-72.
[24]Lee HS, Kim SK, Han JB, et al. Inhibitory effects of Rumex japonicus Houtt on the development of atopic dermatitis-like skin lesions in NC/Nga mice[J]. Br J Dermatol,2006,155(1):33-8.
[25]Yano S, Umeda D, Yamashita S, et al. Dietary apigenin attenuates the development of atopic dermatitis-like skin lesions in NC/Nga mice[J]. J Nutr Biochem,2009,20(11):876-81.
[26]Choi MS, Kim EC, Lee HS et al. Inhibitory Effects of Saururus chinensis (LOUR.) BAILL on the Development of Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice[J].Biol Pharm Bull,2008,31(1):51-6.
[27]Joo SS, Won TJ, Nam SY et al. Therapeutic Advantages of Medicinal Herbs fermented with Lactobacillus plantarum, in Topical Application and its Activities on Atopic Dermatitis[J]. Phytother Res,2009,23(7):913-9.
[28]Chan BC, Hon KL, Leung PC et al. Traditional Chinese medicine for atopic eczema:PentaHerbs formula suppresses inflammatory mediators release from mast cells[J]. J Ethnopharmacol,2008,120(1):85-91.
[29]Lee J, Jung E, Park B et al. Evaluation of the anti-inflammatory and atopic dermatitis-mitigating effects of BSASM, a multicompound preparation[J]. J Ethnopharmacol,2005,96(1-2):211-9.
[30]Mainardi T, Kapoor S, Bielory L et al. Complementary and alternative medicine:Herbs, phytochemicals and vitamins and their immunologic effects[J]. J Allergy Clin Immunol,2009,123(2):283-94.
[31]FOCKE M, SESZTAK-GREINECKER G, BRANNATH W. Plasma levels of polyunsaturated fatty acids in children with atopic dermatitis and in atopic and non-atopic controls[J]. The Middle European Journal of Medicine,2005,117(14):485-491.
[32]CALDER PC. Abnormal fatty acid profiles occur in atopic dermatitis but what do they mean?[J]. Clin Exp Allergy,2006,36(2):138-141.
[33]刘彬,吴宏娟,吴升华等.脂氧素A4抑制实验性皮肤炎症与增殖反应的机制[J].中国皮肤性病学杂志,2005,19(7)：391-394.
[34]YEN CH, DAI YH, YANG YH. Linoleic acid metabolite levels and transepidermal water loss in children with atopic dermatitis [J]. Ann Allergy Asthma Immunol, 2008,100:66-73.
[35]YOON S, LEE J, LEE S. The Therapeutic Effect of Evening Primrose Oil in Atopic Dermatitis Patients with Dry Scaly Skin Lesions is associated with the normalization of serum gamma-interferon levels[J]. Skin Pharmacol Appl Skin Physiol,2002,15:20-25.
[36]MORSE NL, CLOUGH PM. A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries[J]. Curr Pharm Biotechnol,2006,7(6):503-24.
[37]VAN GOOL CJ, THIJS C, HENQUET CJ. Oral essential fatty acid supplementation in atopic dermatitis a meta-analysis of placebo-controlled trials[J]. Br J Dermatol,2004,150(4):728-40.
[38]KANEHARA S, OHTANI T, UEDE K. Clinical effects of undershirts coated with borage oil on children with atopic dermatitis:a double-blind, placebo-controlled clinical trial[J]. J Dermatol,2007,34(12):811-5.
[39]VAN GOOL CJ, THIJS C, HENQUET CJ. Gamma-Linolenic acid supplementation for prophylaxis of atopic dermatitis a randomized controlled trial in infants at high familial risk[J]. Am J Clin Nutr,2003,77:943-51.
[40]KITZ R, ROSE MA, SCHONBORN H. Impact of early dietary gamma-linolenic acid supplementation on atopic eczema in infancy [J]. Pediatr Allergy Immunol, 2006,17(2):112-7.
[41]Beyreiss J, Roth N, Beyer H etal. Coincidence of immune (atopic dermatitis) and behavioral (attention deficit) disorders in children:empirical data[J]. Act Nerv Super (Praha),1988,30(2):127-8.
[42]Pourpak Z, Sedighipour L, Firooz A, et al. Behavioral characteristics in 3-to 12-month-old infant with atopic dermatitis:a case-control study[J].Pediatr Allergy Immunol,2007,18(4):339-45.
[43]Chamlin S, Mattson C, Frieden I, Williams ML, Mancini AJ, Cella D, et al. The price of pruritus:sleep disturbance and cosleeping in atopic dermatitis[J]. Arch Pediatr Adolesc Med,2005,159:745-50.
[44]Reuveni H, Chapnick G, Tal A, Tarasiuk A. Sleep fragmentation in children with atopic dermatitis[J]. Arch Pediatr Adolesc Med,1999,153:249-253
[45]Kapsimalis F, Richardson G. Cytokines and normal sleep[J]. Curr Opin Pulm Med,2005,11:481-4.
[46]Bender BG, Ballard R, Canono B, Disease severity, scratching, and sleep quality in patients with atopic dermatitis[J]. J Am Acad Dermatol,2008,58:415-20.
[47]Majde J, Krueger J. Links between the innate immune system and sleep[J]. J Allergy Clin Immunol,2005,116:1188-98.
[48]Bender BG, Leung DY. Sleep disorders in patients with asthma, atopic dermatitis and allergic rhinitis [J]. JAllergy Clin Imunol,2005,116(6):1200-1.
[49]Leo HL, Bender BG, Leung SB et al. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis[J]. J Allergy Clin Immunol,2004,114:691-693.
[50]Short Sleep Duration and Behavioral Symptoms of Attention-Deficit-/Hyperactivity Disorder in Healthy 7-8-Year-Old Children[J]. Pediatrics, 2009,123(5):857-64.
[51]冯军坛,朱彦丽,王立文.注意缺陷多动障碍综合征患儿睡眠结构的初探[J].中国循证儿科杂志,2007,2(4)：273.
[52]Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S Sleep disturbances in children with atopic dermatitis[J].Arch Pediatr Adolesc Med, 1995,149(8):856-60.
[53]Chng SY, Goh DY, Wang XS. Snoring and atopic disease:a strong association[J]. Pediatr Pulmonol,2004,38(3):210-6.
[54]李介民,胡劲涛,蔡益民等.3-5岁儿童打鼾与行为问题的相关性研究[J].中国全科医学,2009,12(9A)：1603—1605.
[55]Shani-Adir A, Rozenman D, Kessel A, et, al. The relationship between sensory hypersensitivity and sleep quality of children with atopic dermatitis[J]. Pediatr Dermatol,2009,26(2):143-9.
[56]Bender BG, Leung DY. Sleep disorders in patients with asthma, atopic dermatitis, and allergic rhinitis[J]. J Allergy Clin Immunol,2005,116:1200-1201.
[57]Engel-Yeger B, Habib-Mazawi S, Parush S et al. The sensory profile of children with atopic dermatitis as determined by the sensory profile questionnaire[J].J Am Acad Dermatol,2007,57 (4):610-615.
[58]Kimata H. Viewing humorous film improves nighttime wakening in children with atopic dermatitis[J]. Indian Pediatr,2007,44:281-285.
[59]GuneliE, KazikdasKC, KolatanE. Ghrelinmay attenuate proinflammatory cytokine-mediated neuropathic pain[J].Med Hypotheses,2007,69:356-360.
[60]Kelsay K. Management of sleep disturbance associated with atopic dermatitis[J].J Allerg Clin Immunol,2006,118:198-201.
[61]Warschburger P, Buchholtz HT, Petermann F. Psychological adjustment in parents of young children with atopic dermatitis:which factors predict parental quality of life? [J].Br J Dermatol,2004,150:304-311.
[62]Polanczyk G, Silva de Lima MS, Horta BL, The worldwide prevalence of ADHD: a systematic review and metaregression analysis[J]. Am J Psychiatry, 2007,164(6):942-948.
[63]Roth N, Beyreiss J, Schlenzka K, et al. Coincidence of attention deficit disorder and atopic disorders in children:empirical findings and hypothetical background[J].J Abnorm Child Psychol,1991,19:1-13.
[64]Schmitt J, Romanos M, Schmitt NM, et al. Atopic eczema and attentiondeficit/hyperactivity disorder in a population-based sample of children and adolescents[J]. JAMA,2009,301:724-6.
[65]Romanos M, Gerlach M, Warnke A. Association of attention-deficit-/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample[J].J Epidemiol Community Health,2009:1-15
[66]Short Sleep Duration and Behavioral Symptoms of Attention-Deficit-/Hyperactivity Disorder in Healthy 7-8-Year-old Children[J]. Pediatrics, 2009,123(5):857-64.
[67]Nemoto-Hasebe I, Akiyama M, Nomura T, Sandilands A, McLean WH, Shimizu H. Clinical severity correlates with impaired barrier in filaggrin-related eczema[J]. J Invest Dermatol,2009,129:682-689.
[68]Wakamori T, Katoh N, Hirano S, Kishimoto S, Ozasa K. Atopic dermatitis, dry skin and serum IgE in children in a community in Japan[J]. Int Arch Allergy Immunol,2009,149:103-110.
[69]Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis:outside-inside-outside pathogenic mechanisms [J]. J Allergy Clin Immunol,2008,121:1337-1343
[70]Haratake A, Ikenaga K, Katoh N, Uchiwa H, Hirano S,Yasuno H. Topical mevalonic acid stimulates de novocholesterol synthesis and epidermal permeabilitybarrier homeostasis in aged mice[J]. J Invest Dermatol,2000,114: 247-252.
[71]Tanno 0, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve theepidermal permeability barrier [J]. Br J Dermatol,2000,143:524-531.
[72]Nin M, Katoh N, Kokura S, Handa 0, Yoshikawa T, Kishimoto S. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes[J]. J Dermatol Sci,2009,54:17-24.
[73]Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis:meta-analysis of randomized controlled trials[J]. BMJ,2005,330: 516.
[74]Luger T, Van Leent EJ, Graeber M et al.SDZ ASM 981:an emerging safe and effective treatment for atopic dermatitis[J]. Br J Dermatol,2001,144:788-794
[75]Abramovits W.Fleischer AB Jr, Jaracz E, Breneman D. Adult patients with moderate atopic dermatitis:tacrolimus ointment versus pimecrolimus cream[J].J Drugs Dermatol,2008,7:1153-1158.
[76]Katoh N, Hirano S, Yasuno H, Kishimoto S. Effects of tacrolimus ointment on facial eruption, itch, and scratching in patients with atopic dermatitis [J]. J Dermatol,2004,31:194-199.
[77]Inoue T, Katoh N, Kishimoto S. Prolonged topical application of tacrolimus inhibits immediate hypersensitivity reactions by reducing degranulation of mast cells[J]. Acta Derm Venereol,2006,86:13-16.
[78]Senba E,Katanosaka K, Yajima H, Mizumura K. The immunosuppressant FK506 activates capsaicin-and bradykinin-sensitive DRG neurons and cutaneous C-fibers[J]. Neurosci Res,2004,50:257-262.
[79]Munzenberger PJ, Monte jo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis[J]. Pharmacotherapy,2007,27:1020-1028.
[80]Wollenberg A, Frank R, Kroth J, Proactive therapy of atopic eczema-an evidence-based concept with a behavioral background [J]. JDDG,2009,7:117-121.
[81]Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse inatopic dermatitis:randomised, double blind, parallel group study[J]. BMJ,2003,326:1367.
[82]Greaves MW. Recent advances in pathophysiology and current management of itch[J].Ann Acad Med Singapore,2007,36:788-792.
[83]Klein PA, Clark RA.An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis[J]. Arch Dermatol,1999,5:1522-1525.
[84]Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults:European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report[J].J Allergy Clin Immunol,2006,118:152-169.
[85]Ikoma A, Steinhof f M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci,2006,7:535-547.
[86]Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of itch[J]. Nat Rev Neurosci,2006,7:535-547
[87]Bilsborough J, Leung DY, Maurer M et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis [J]. J Allergy Clin Immunol,2006,117:418-425
[88]Bilsborough J, Leung DY, Maurer M et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis [J]. J Allergy Clin Immunol,2006,117:418-425
[89]Tominaga M, Ozawa S, Tengara S, Ogawa H, Takamori K. Intraepidermal nerve fibers increase in dry skin of acetone-treated mice [J]. J Dermatol Sci,2007,48: 103-111.
[90]Yamaguchi J, Nakamura F, Aihara M, et al. Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model [J]. J Invest Dermatol,2008,128:2842-2849.
[91]Mukai K, Matsuoka K, Taya C et al. Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of T cells and mast cells [J]. Immunity,2005,23:191-202.
[92]Obata K, Mukai K, Tsujimura Y et al. Basophils are essential initiators of a novel type of chronic allergic inflammation[J]. Blood,2007,110:913-920
[93]Allakhverdi Z, Comeau MR, Jessup HK et al. Thymicstromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflamation and potently activates mast cells [J]. J Exp Med,2007,204:253-258.
[94]Katoh N. Platelet as versatile regulators of cutaneous inflammation [J]. J Dermatol Sci,2009,53:89-95.
[95]Soga F, Katoh N, Inoue T, Kishimoto S. Serotonin activates human monocytes and prevents apoptosis[J]. J Invest Dermatol,2007,127:1947-1955.
[96]Tamagawa-Mineoka R, Katoh N, Ueda E, et al. Platelet-derived microparticles and soluble P-selectin as platelet activation markers in patients with atopic dermatitis.[J].Clin Immunol,2009,131:495-500.
[97]Tamagawa-Mineoka R, Katoh N, Ueda E, Takenaka H, Kita M, Kishimoto S. The role of platelets in leukocyte recruitment in chronic contact hypersensitivity induced by repeated elicitation[J].Am J Pathol,2007,170:2019-2029.
[98]Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelets play important roles in the late phase of the immediate hypersensitivity reaction[J]. J Allergy Clin Immunol,2009,123:581-587.
[99]郝飞,宋志强.特应性皮炎[M].北京：人民军医出版社,2008：398.
[100]Darsow U, Wollenberg A, Simon D.ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis [J].J Eur Acad Dermatol Venereol,2009:1-12.
[101]Watanabe M, Satoh T, Yamamoto Y, Kanai Y, Karasuyama H,Yokozeki H. Overproduction of IgE induces macrophage-derived chemokine (CCL22) secretion from basophils[J].J Immunol,2008,181:5653-5659.
[102]Katoh N, Kraft S, Wessendorf JH, et al. The high affinity IgE receptor block apoptosis in normal human monocytes[J]. J Clin Invest,2000,105:183-190.
[103]Holgate ST, Djukananovic R, Casale T. Anti-immunoglobulin E treatment with omalizumab in allergic diseases. An update on anti-inflammatory activity and clinical. efficacy[J]. Clin Exp Allergy,2005,35:408-416.
[104]Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab[J]. J Am Acad Dermatol,2006,15:68-72.
[105]Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis[J]. J Am Acad Dermatol,2005,53:338-340.
[106]BuBmann C, Bieber T, Novak N. Systemic therapeutic options for severe atopic dermatitis[J]. J Dtsch Dermatol Ges,2009,7:205-219.
[107]Belloni B, Andres C, Ollert M, Ring J, Mempel M. Novel immunological approaches in the treatment of atopic eczema[J].Curr Opin Allergy Clin Immunol,2008,8:423-427.
[108]Werfel T, Breuer K, Rueff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites:a multi-centre, randomized, dose-response study[J]. Allergy,2006,61:202-205.
[109]Katoh N. Future perspectives in the treatment of atopic dermatitis [J]. J Dermatol,2009,36(7):367-76.
[110]Senti G, Steinmann L. S, Fische B. Antimicrobial Silk Clothing in the Treatment of Atopic Dermatitis Proves Comparable to Topical Corticosteroid Treatment[J]. Dermatology,2006,213:228-233.
[111]Eleanor J. Kurtz, B. S. E. E., Christopher B. Yelverton er al. Use of a Silklike Bedding Fabric in Patients with Atopic Dermatitis[J]. Pediatric Dermatology,2008,25(4):439-443.
[112]Whole-Body Cryotherapy in Atopic Dermatitis [J]. ARCH DERMATOL,2008,144 (6):806-808.
[113]范娟,杜亚松,王立伟.Conner父母用症状问卷的中国城市常模和信度研究[J].上海精神医学,2005,17(6)：321：323.
[114]Wamboldt MZ, Schmitz S, Mrazek D. Genetic association between atopy and behavioral symptoms in middle childhood[J]. J Child Psychol Psychiatry, 1998,9 (7):1007-16.
[115]苏林雁,李雪荣,黄春香等.Conners父母症状问卷的中国城市常模[J].中国临床心理学杂志,2001,(9)4：241-243.
[116]Absolon CM, Cottrell D, Eldridge SM, Psychological disturbance in atopic eczema:the extent of the problem in school-aged children[J].Br J Dermatol, 1997,137(2):241-5.
[117]Garrie SA, Garrie EV. Anxiety and skin diseases [J]. Cutis,1978,22(2): 205-208.
[118]Sarkar R, Raj L, Kaur H, Psychological disturbances in Indian children with atopic eczema[J].J Dermatol,2004,31(6):448-54.
[119]Pourpak Z, Sedighipour L, Firooz A, Afrooz A et al. Behavioral characteristics in 3 to 12-month-old infant with atopic dermatitis:a case-control study[J]. Pediatr Allergy Immunol,2007,18(4):339-45.
[120]杜亚松.儿童心理卫生保健[M].上海：上海科学技术出版社,1999：158-160.
[121]YEN CH, DAI YH, YANG YH. Linoleic acid metabolite levels and transepidermal water loss in children with atopic dermatitis [J]. Ann Allergy Asthma Immunol,2008,100:66-73.
[122]王朋.脾运化功能是脂质代谢的关键[J].江西中医学院学报,2008,20(3)：23-24.
[123]Kaku S, Ohkura K, Yunoki S. Dietary gamma-linolenic acid dose-dependently modifies fatty acid composition and immune parameters in rats[J]. Prostaglandins Leukot Essent Fatty Acids,2001,65(4):205-10.
[124]Sung-pil Y, JOO-heung L, Seung Chul L. Gamma-linolenic acid improves atopic dermatitis by Gamma-interferon and immunoglobulin-E modultion[J]. SID Abstracts:s 208.
[125]Jiang WG, Puntis MC, Horrobin DF. Inhibition of neutrophil respiratory burst and cytokine priming by gamma-linolenic acid[J]Br J Surg, 1996,83 (5):659-64.
[2]邢华,朱仁康.治疗异位性皮炎的经验[J].中华中医药学刊,2007,25(2)：229-230.
[3]何丹,林青,王妍.特应性皮炎的中医辨证及用药规律[J].云南中医学院学报,2009,32(4)：66-70.
[4]尤立平,刘永生,杨顶权,等.44例特应性皮炎中医临床证候分析与辨证治疗[J]中国中西医结合皮肤性病学杂志,2003,2(2)：71-73.
[5]王文革.汪受传教授治疗异位性皮炎的经验[J].中华中医药杂志,2008,23(8)：703-704.
[6]吕飞,周春燕.辨证治疗异位性皮炎[J].中国民间疗法,2004,12(6)：8-9.
[7]秦万章.先天性过敏性湿疹的证治[J].中国中西医结合杂志,2008,28(8)：677-678.
[8]Kasperska-Zajac A, Brzoza Z, Koczy-Baron E, et al. Blood Rheological Properties in Patients with Atopic Dermatitis(AD)[J]. Inflammation. 2009,32(4):242-6.
[9]姚守恩,周渐云许铣治疗异位性皮炎经验[J].实用中医药杂志,2006,22(2)：116.
[10]刘汉长.中医内外合治特应性皮炎疗效观察[J].世界中西医结合杂志,2006,1(3)：166—167.
[11]欧柏生,刘卫兵,王建民.四弯风汤联合西药治疗特异性皮炎34例[J].中国民间疗法,2006,14(1)：8-9.
[12]杨瑛,孙继兰,王麦娣,等.健脾止痒颗粒治疗特应性皮炎临床观察[J].中国皮肤性病学杂志,2005,19(12)：755-756.
[13]麻林玖,梁红梅.加味启脾丸颗粒治疗儿童特应性皮炎疗效观察[J].中国皮肤性病学杂志,2006,20(11)：698.
[14]陈文展.黛连油膏治疗异位性皮炎26例[J].福建医药杂志,2003,25(3)：224—225.
[15]关小红,张立曼.润肤止痒洗剂治疗特应性皮炎54例临床观察[J].中国中西医结合皮性病学杂志,2006,5(2)：113.
[16]陈骏铎.陆怀橘干湿法治疗异位性皮炎[J].中国民间疗法,1999,15(3)：5
[17]曾昭明,潘伟军.中药内服外用治疗异位性皮炎47例[J].新中医,2007,39(3)：56—57.
[18]Hon KL, Leung TF, Ng PC et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis:a randomized, double-blind, placebo-controlled study[J]. Br J Dermatol,2007,157(2):357-63.
[19]Leung TF, Wong KY, Wong CK, et al. In vitro and clinical immunomodulatory effects of a novel Pentaherbs concoction for atopic dermatitis[J]. Br J Dermatol,2008,158(6):1216-23.
[20]Salameh F, Perla D, Solomon M-et al. The Effectiveness of Combined Chinese Herbal Medicine and Acupuncture in the Treatment of Atopic Dermatitis[J]. J Altern Complement Med,2008,14(8):1043-8.
[21]Kim J, Kim Y, Seo D et al. Oral supplementation of Lithospermum erythrorhizon prevents the development of atopic dermatitis with reducing ceramide degradation in the epidermis of NC/Nga mice[J]. Phytother Res, 2009,23 (9):1250-6.
[22]Lee JH, Jung KM, Bae IH et al. Anti-inflammatory and barrier protecting effect of Lithospermum erythrorhizon extracts in chronic oxazolone-induced murine atopic dermatitis[J]. J Dermatol Sci,2009,56(1):64-66
[23]Kim DY, Jung JA, Kim TH et al, Oral administration of Uncariae rhynchophylla inhibits the development of DNFB-induced atopic dermatitis-like skin lesions via IFN-gamma down-regulation in NC/Nga mice[J].J Ethnopharmacol, 2009,122(3):567-72.
[24]Lee HS, Kim SK, Han JB, et al. Inhibitory effects of Rumex japonicus Houtt on the development of atopic dermatitis-like skin lesions in NC/Nga mice[J]. Br J Dermatol,2006,155(1):33-8.
[25]Yano S, Umeda D, Yamashita S, et al. Dietary apigenin attenuates the development of atopic dermatitis-like skin lesions in NC/Nga mice[J]. J Nutr Biochem,2009,20(11):876-81.
[26]Choi MS, Kim EC, Lee HS et al. Inhibitory Effects of Saururus chinensis (LOUR.) BAILL on the Development of Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice[J].Biol Pharm Bull,2008,31(1):51-6.
[27]Joo SS, Won TJ, Nam SY et al. Therapeutic Advantages of Medicinal Herbs fermented with Lactobacillus plantarum, in Topical Application and its Activities on Atopic Dermatitis[J]. Phytother Res,2009,23(7):913-9.
[28]Chan BC, Hon KL, Leung PC et al. Traditional Chinese medicine for atopic eczema:PentaHerbs formula suppresses inflammatory mediators release from mast cells[J]. J Ethnopharmacol,2008,120(1):85-91.
[29]Lee J, Jung E, Park B et al. Evaluation of the anti-inflammatory and atopic dermatitis-mitigating effects of BSASM, a multicompound preparation[J]. J Ethnopharmacol,2005,96(1-2):211-9.
[30]Mainardi T, Kapoor S, Bielory L et al. Complementary and alternative medicine:Herbs, phytochemicals and vitamins and their immunologic effects[J]. J Allergy Clin Immunol,2009,123(2):283-94.
[31]FOCKE M, SESZTAK-GREINECKER G, BRANNATH W. Plasma levels of polyunsaturated fatty acids in children with atopic dermatitis and in atopic and non-atopic controls[J]. The Middle European Journal of Medicine,2005,117(14):485-491.
[32]CALDER PC. Abnormal fatty acid profiles occur in atopic dermatitis but what do they mean?[J]. Clin Exp Allergy,2006,36(2):138-141.
[33]刘彬,吴宏娟,吴升华等.脂氧素A4抑制实验性皮肤炎症与增殖反应的机制[J].中国皮肤性病学杂志,2005,19(7)：391-394.
[34]YEN CH, DAI YH, YANG YH. Linoleic acid metabolite levels and transepidermal water loss in children with atopic dermatitis [J]. Ann Allergy Asthma Immunol, 2008,100:66-73.
[35]YOON S, LEE J, LEE S. The Therapeutic Effect of Evening Primrose Oil in Atopic Dermatitis Patients with Dry Scaly Skin Lesions is associated with the normalization of serum gamma-interferon levels[J]. Skin Pharmacol Appl Skin Physiol,2002,15:20-25.
[36]MORSE NL, CLOUGH PM. A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries[J]. Curr Pharm Biotechnol,2006,7(6):503-24.
[37]VAN GOOL CJ, THIJS C, HENQUET CJ. Oral essential fatty acid supplementation in atopic dermatitis a meta-analysis of placebo-controlled trials[J]. Br J Dermatol,2004,150(4):728-40.
[38]KANEHARA S, OHTANI T, UEDE K. Clinical effects of undershirts coated with borage oil on children with atopic dermatitis:a double-blind, placebo-controlled clinical trial[J]. J Dermatol,2007,34(12):811-5.
[39]VAN GOOL CJ, THIJS C, HENQUET CJ. Gamma-Linolenic acid supplementation for prophylaxis of atopic dermatitis a randomized controlled trial in infants at high familial risk[J]. Am J Clin Nutr,2003,77:943-51.
[40]KITZ R, ROSE MA, SCHONBORN H. Impact of early dietary gamma-linolenic acid supplementation on atopic eczema in infancy [J]. Pediatr Allergy Immunol, 2006,17(2):112-7.
[41]Beyreiss J, Roth N, Beyer H etal. Coincidence of immune (atopic dermatitis) and behavioral (attention deficit) disorders in children:empirical data[J]. Act Nerv Super (Praha),1988,30(2):127-8.
[42]Pourpak Z, Sedighipour L, Firooz A, et al. Behavioral characteristics in 3-to 12-month-old infant with atopic dermatitis:a case-control study[J].Pediatr Allergy Immunol,2007,18(4):339-45.
[43]Chamlin S, Mattson C, Frieden I, Williams ML, Mancini AJ, Cella D, et al. The price of pruritus:sleep disturbance and cosleeping in atopic dermatitis[J]. Arch Pediatr Adolesc Med,2005,159:745-50.
[44]Reuveni H, Chapnick G, Tal A, Tarasiuk A. Sleep fragmentation in children with atopic dermatitis[J]. Arch Pediatr Adolesc Med,1999,153:249-253
[45]Kapsimalis F, Richardson G. Cytokines and normal sleep[J]. Curr Opin Pulm Med,2005,11:481-4.
[46]Bender BG, Ballard R, Canono B, Disease severity, scratching, and sleep quality in patients with atopic dermatitis[J]. J Am Acad Dermatol,2008,58:415-20.
[47]Majde J, Krueger J. Links between the innate immune system and sleep[J]. J Allergy Clin Immunol,2005,116:1188-98.
[48]Bender BG, Leung DY. Sleep disorders in patients with asthma, atopic dermatitis and allergic rhinitis [J]. JAllergy Clin Imunol,2005,116(6):1200-1.
[49]Leo HL, Bender BG, Leung SB et al. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis[J]. J Allergy Clin Immunol,2004,114:691-693.
[50]Short Sleep Duration and Behavioral Symptoms of Attention-Deficit-/Hyperactivity Disorder in Healthy 7-8-Year-Old Children[J]. Pediatrics, 2009,123(5):857-64.
[51]冯军坛,朱彦丽,王立文.注意缺陷多动障碍综合征患儿睡眠结构的初探[J].中国循证儿科杂志,2007,2(4)：273.
[52]Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S Sleep disturbances in children with atopic dermatitis[J].Arch Pediatr Adolesc Med, 1995,149(8):856-60.
[53]Chng SY, Goh DY, Wang XS. Snoring and atopic disease:a strong association[J]. Pediatr Pulmonol,2004,38(3):210-6.
[54]李介民,胡劲涛,蔡益民等.3-5岁儿童打鼾与行为问题的相关性研究[J].中国全科医学,2009,12(9A)：1603—1605.
[55]Shani-Adir A, Rozenman D, Kessel A, et, al. The relationship between sensory hypersensitivity and sleep quality of children with atopic dermatitis[J]. Pediatr Dermatol,2009,26(2):143-9.
[56]Bender BG, Leung DY. Sleep disorders in patients with asthma, atopic dermatitis, and allergic rhinitis[J]. J Allergy Clin Immunol,2005,116:1200-1201.
[57]Engel-Yeger B, Habib-Mazawi S, Parush S et al. The sensory profile of children with atopic dermatitis as determined by the sensory profile questionnaire[J].J Am Acad Dermatol,2007,57 (4):610-615.
[58]Kimata H. Viewing humorous film improves nighttime wakening in children with atopic dermatitis[J]. Indian Pediatr,2007,44:281-285.
[59]GuneliE, KazikdasKC, KolatanE. Ghrelinmay attenuate proinflammatory cytokine-mediated neuropathic pain[J].Med Hypotheses,2007,69:356-360.
[60]Kelsay K. Management of sleep disturbance associated with atopic dermatitis[J].J Allerg Clin Immunol,2006,118:198-201.
[61]Warschburger P, Buchholtz HT, Petermann F. Psychological adjustment in parents of young children with atopic dermatitis:which factors predict parental quality of life? [J].Br J Dermatol,2004,150:304-311.
[62]Polanczyk G, Silva de Lima MS, Horta BL, The worldwide prevalence of ADHD: a systematic review and metaregression analysis[J]. Am J Psychiatry, 2007,164(6):942-948.
[63]Roth N, Beyreiss J, Schlenzka K, et al. Coincidence of attention deficit disorder and atopic disorders in children:empirical findings and hypothetical background[J].J Abnorm Child Psychol,1991,19:1-13.
[64]Schmitt J, Romanos M, Schmitt NM, et al. Atopic eczema and attentiondeficit/hyperactivity disorder in a population-based sample of children and adolescents[J]. JAMA,2009,301:724-6.
[65]Romanos M, Gerlach M, Warnke A. Association of attention-deficit-/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample[J].J Epidemiol Community Health,2009:1-15
[66]Short Sleep Duration and Behavioral Symptoms of Attention-Deficit-/Hyperactivity Disorder in Healthy 7-8-Year-old Children[J]. Pediatrics, 2009,123(5):857-64.
[67]Nemoto-Hasebe I, Akiyama M, Nomura T, Sandilands A, McLean WH, Shimizu H. Clinical severity correlates with impaired barrier in filaggrin-related eczema[J]. J Invest Dermatol,2009,129:682-689.
[68]Wakamori T, Katoh N, Hirano S, Kishimoto S, Ozasa K. Atopic dermatitis, dry skin and serum IgE in children in a community in Japan[J]. Int Arch Allergy Immunol,2009,149:103-110.
[69]Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis:outside-inside-outside pathogenic mechanisms [J]. J Allergy Clin Immunol,2008,121:1337-1343
[70]Haratake A, Ikenaga K, Katoh N, Uchiwa H, Hirano S,Yasuno H. Topical mevalonic acid stimulates de novocholesterol synthesis and epidermal permeabilitybarrier homeostasis in aged mice[J]. J Invest Dermatol,2000,114: 247-252.
[71]Tanno 0, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve theepidermal permeability barrier [J]. Br J Dermatol,2000,143:524-531.
[72]Nin M, Katoh N, Kokura S, Handa 0, Yoshikawa T, Kishimoto S. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes[J]. J Dermatol Sci,2009,54:17-24.
[73]Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis:meta-analysis of randomized controlled trials[J]. BMJ,2005,330: 516.
[74]Luger T, Van Leent EJ, Graeber M et al.SDZ ASM 981:an emerging safe and effective treatment for atopic dermatitis[J]. Br J Dermatol,2001,144:788-794
[75]Abramovits W.Fleischer AB Jr, Jaracz E, Breneman D. Adult patients with moderate atopic dermatitis:tacrolimus ointment versus pimecrolimus cream[J].J Drugs Dermatol,2008,7:1153-1158.
[76]Katoh N, Hirano S, Yasuno H, Kishimoto S. Effects of tacrolimus ointment on facial eruption, itch, and scratching in patients with atopic dermatitis [J]. J Dermatol,2004,31:194-199.
[77]Inoue T, Katoh N, Kishimoto S. Prolonged topical application of tacrolimus inhibits immediate hypersensitivity reactions by reducing degranulation of mast cells[J]. Acta Derm Venereol,2006,86:13-16.
[78]Senba E,Katanosaka K, Yajima H, Mizumura K. The immunosuppressant FK506 activates capsaicin-and bradykinin-sensitive DRG neurons and cutaneous C-fibers[J]. Neurosci Res,2004,50:257-262.
[79]Munzenberger PJ, Monte jo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis[J]. Pharmacotherapy,2007,27:1020-1028.
[80]Wollenberg A, Frank R, Kroth J, Proactive therapy of atopic eczema-an evidence-based concept with a behavioral background [J]. JDDG,2009,7:117-121.
[81]Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse inatopic dermatitis:randomised, double blind, parallel group study[J]. BMJ,2003,326:1367.
[82]Greaves MW. Recent advances in pathophysiology and current management of itch[J].Ann Acad Med Singapore,2007,36:788-792.
[83]Klein PA, Clark RA.An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis[J]. Arch Dermatol,1999,5:1522-1525.
[84]Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults:European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report[J].J Allergy Clin Immunol,2006,118:152-169.
[85]Ikoma A, Steinhof f M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci,2006,7:535-547.
[86]Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of itch[J]. Nat Rev Neurosci,2006,7:535-547
[87]Bilsborough J, Leung DY, Maurer M et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis [J]. J Allergy Clin Immunol,2006,117:418-425
[88]Bilsborough J, Leung DY, Maurer M et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis [J]. J Allergy Clin Immunol,2006,117:418-425
[89]Tominaga M, Ozawa S, Tengara S, Ogawa H, Takamori K. Intraepidermal nerve fibers increase in dry skin of acetone-treated mice [J]. J Dermatol Sci,2007,48: 103-111.
[90]Yamaguchi J, Nakamura F, Aihara M, et al. Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model [J]. J Invest Dermatol,2008,128:2842-2849.
[91]Mukai K, Matsuoka K, Taya C et al. Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of T cells and mast cells [J]. Immunity,2005,23:191-202.
[92]Obata K, Mukai K, Tsujimura Y et al. Basophils are essential initiators of a novel type of chronic allergic inflammation[J]. Blood,2007,110:913-920
[93]Allakhverdi Z, Comeau MR, Jessup HK et al. Thymicstromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflamation and potently activates mast cells [J]. J Exp Med,2007,204:253-258.
[94]Katoh N. Platelet as versatile regulators of cutaneous inflammation [J]. J Dermatol Sci,2009,53:89-95.
[95]Soga F, Katoh N, Inoue T, Kishimoto S. Serotonin activates human monocytes and prevents apoptosis[J]. J Invest Dermatol,2007,127:1947-1955.
[96]Tamagawa-Mineoka R, Katoh N, Ueda E, et al. Platelet-derived microparticles and soluble P-selectin as platelet activation markers in patients with atopic dermatitis.[J].Clin Immunol,2009,131:495-500.
[97]Tamagawa-Mineoka R, Katoh N, Ueda E, Takenaka H, Kita M, Kishimoto S. The role of platelets in leukocyte recruitment in chronic contact hypersensitivity induced by repeated elicitation[J].Am J Pathol,2007,170:2019-2029.
[98]Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelets play important roles in the late phase of the immediate hypersensitivity reaction[J]. J Allergy Clin Immunol,2009,123:581-587.
[99]郝飞,宋志强.特应性皮炎[M].北京：人民军医出版社,2008：398.
[100]Darsow U, Wollenberg A, Simon D.ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis [J].J Eur Acad Dermatol Venereol,2009:1-12.
[101]Watanabe M, Satoh T, Yamamoto Y, Kanai Y, Karasuyama H,Yokozeki H. Overproduction of IgE induces macrophage-derived chemokine (CCL22) secretion from basophils[J].J Immunol,2008,181:5653-5659.
[102]Katoh N, Kraft S, Wessendorf JH, et al. The high affinity IgE receptor block apoptosis in normal human monocytes[J]. J Clin Invest,2000,105:183-190.
[103]Holgate ST, Djukananovic R, Casale T. Anti-immunoglobulin E treatment with omalizumab in allergic diseases. An update on anti-inflammatory activity and clinical. efficacy[J]. Clin Exp Allergy,2005,35:408-416.
[104]Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab[J]. J Am Acad Dermatol,2006,15:68-72.
[105]Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis[J]. J Am Acad Dermatol,2005,53:338-340.
[106]BuBmann C, Bieber T, Novak N. Systemic therapeutic options for severe atopic dermatitis[J]. J Dtsch Dermatol Ges,2009,7:205-219.
[107]Belloni B, Andres C, Ollert M, Ring J, Mempel M. Novel immunological approaches in the treatment of atopic eczema[J].Curr Opin Allergy Clin Immunol,2008,8:423-427.
[108]Werfel T, Breuer K, Rueff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites:a multi-centre, randomized, dose-response study[J]. Allergy,2006,61:202-205.
[109]Katoh N. Future perspectives in the treatment of atopic dermatitis [J]. J Dermatol,2009,36(7):367-76.
[110]Senti G, Steinmann L. S, Fische B. Antimicrobial Silk Clothing in the Treatment of Atopic Dermatitis Proves Comparable to Topical Corticosteroid Treatment[J]. Dermatology,2006,213:228-233.
[111]Eleanor J. Kurtz, B. S. E. E., Christopher B. Yelverton er al. Use of a Silklike Bedding Fabric in Patients with Atopic Dermatitis[J]. Pediatric Dermatology,2008,25(4):439-443.
[112]Whole-Body Cryotherapy in Atopic Dermatitis [J]. ARCH DERMATOL,2008,144 (6):806-808.
[113]范娟,杜亚松,王立伟.Conner父母用症状问卷的中国城市常模和信度研究[J].上海精神医学,2005,17(6)：321：323.
[114]Wamboldt MZ, Schmitz S, Mrazek D. Genetic association between atopy and behavioral symptoms in middle childhood[J]. J Child Psychol Psychiatry, 1998,9 (7):1007-16.
[115]苏林雁,李雪荣,黄春香等.Conners父母症状问卷的中国城市常模[J].中国临床心理学杂志,2001,(9)4：241-243.
[116]Absolon CM, Cottrell D, Eldridge SM, Psychological disturbance in atopic eczema:the extent of the problem in school-aged children[J].Br J Dermatol, 1997,137(2):241-5.
[117]Garrie SA, Garrie EV. Anxiety and skin diseases [J]. Cutis,1978,22(2): 205-208.
[118]Sarkar R, Raj L, Kaur H, Psychological disturbances in Indian children with atopic eczema[J].J Dermatol,2004,31(6):448-54.
[119]Pourpak Z, Sedighipour L, Firooz A, Afrooz A et al. Behavioral characteristics in 3 to 12-month-old infant with atopic dermatitis:a case-control study[J]. Pediatr Allergy Immunol,2007,18(4):339-45.
[120]杜亚松.儿童心理卫生保健[M].上海：上海科学技术出版社,1999：158-160.
[121]YEN CH, DAI YH, YANG YH. Linoleic acid metabolite levels and transepidermal water loss in children with atopic dermatitis [J]. Ann Allergy Asthma Immunol,2008,100:66-73.
[122]王朋.脾运化功能是脂质代谢的关键[J].江西中医学院学报,2008,20(3)：23-24.
[123]Kaku S, Ohkura K, Yunoki S. Dietary gamma-linolenic acid dose-dependently modifies fatty acid composition and immune parameters in rats[J]. Prostaglandins Leukot Essent Fatty Acids,2001,65(4):205-10.
[124]Sung-pil Y, JOO-heung L, Seung Chul L. Gamma-linolenic acid improves atopic dermatitis by Gamma-interferon and immunoglobulin-E modultion[J]. SID Abstracts:s 208.
[125]Jiang WG, Puntis MC, Horrobin DF. Inhibition of neutrophil respiratory burst and cytokine priming by gamma-linolenic acid[J]Br J Surg, 1996,83 (5):659-64.